ANI Pharmaceuticals’ (ANIP) Buy Rating Reaffirmed at HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $94.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 51.88% from the stock’s current price.

Several other brokerages have also recently issued reports on ANIP. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Trading Up 13.4 %

NASDAQ ANIP opened at $61.89 on Monday. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market capitalization of $1.30 billion, a PE ratio of -112.53 and a beta of 0.74. The company has a fifty day moving average of $57.23 and a 200 day moving average of $58.13.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,300 shares of company stock worth $584,009 over the last 90 days. 12.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Millennium Management LLC grew its position in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. State Street Corp boosted its stake in ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after buying an additional 58,698 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in ANI Pharmaceuticals by 4.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock valued at $37,906,000 after buying an additional 30,420 shares in the last quarter. Deep Track Capital LP increased its stake in shares of ANI Pharmaceuticals by 28.6% in the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after acquiring an additional 144,214 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock worth $34,525,000 after acquiring an additional 88,100 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.